Establishment Labs Holdings Inc (ESTA) Given Consensus Recommendation of “Buy” by Analysts

Shares of Establishment Labs Holdings Inc (NASDAQ:ESTA) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $36.67.

ESTA has been the subject of several research analyst reports. BTIG Research reiterated a “buy” rating and set a $40.00 target price on shares of Establishment Labs in a research note on Thursday, May 16th. ValuEngine downgraded Establishment Labs from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Stephens began coverage on Establishment Labs in a research note on Thursday. They issued an “overweight” rating for the company.

Establishment Labs stock traded down $0.53 during midday trading on Thursday, reaching $22.22. The stock had a trading volume of 26,904 shares, compared to its average volume of 78,878. Establishment Labs has a 1-year low of $20.05 and a 1-year high of $30.70. The firm has a market cap of $475.33 million and a PE ratio of -19.84. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.10 and a current ratio of 5.54.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.13). The company had revenue of $20.78 million for the quarter, compared to analyst estimates of $18.50 million. Establishment Labs had a negative return on equity of 68.22% and a negative net margin of 37.74%. As a group, equities research analysts predict that Establishment Labs will post -1.93 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Establishment Labs in the 3rd quarter valued at about $5,088,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Establishment Labs by 159.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 102,900 shares of the company’s stock worth $2,822,000 after purchasing an additional 63,300 shares during the last quarter. Pura Vida Investments LLC lifted its stake in Establishment Labs by 38.3% in the fourth quarter. Pura Vida Investments LLC now owns 287,399 shares of the company’s stock worth $7,880,000 after purchasing an additional 79,517 shares during the last quarter. Nantahala Capital Management LLC lifted its stake in Establishment Labs by 148.0% in the fourth quarter. Nantahala Capital Management LLC now owns 495,958 shares of the company’s stock worth $13,599,000 after purchasing an additional 295,958 shares during the last quarter. Finally, RTW Investments LP lifted its stake in Establishment Labs by 9.3% in the fourth quarter. RTW Investments LP now owns 848,058 shares of the company’s stock worth $22,740,000 after purchasing an additional 72,249 shares during the last quarter. 25.77% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

Read More: What are Institutional Investors?

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.